¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Çѱ¹À¯¹æ¾ÏÇÐȸ Á¦18ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö : 2022-03-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Çѱ¹À¯¹æ¾ÏÇÐȸ Á¦18ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö : 2022-03-26
±³À°ÀÏÀÚ : 2022-03-26
±³À°Àå¼Ò : ¼­¿ïµå·¡°ï½ÃƼ 5Ãþ ±×·£µåº¼·ë ¹éµÎȦ  
±³À°ÁÖÁ¦ : Á¦18ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö¿µ
¿¬¶ôó : 02-3461-6060  
À̸ÞÀÏ : kbcs@kbcs.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 15ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í Á¤È¸¿ø.ÁØȸ¿ø : 5¸¸¿ø / °£È£»ç.Àü°øÀÇ : 3¸¸¿ø / ºñȸ¿ø : 8¸¸¿ø / 65¼¼ÀÌ»ó : ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-26 ¹éµÎȦ 09:10~09:35 Clinical Applications of Gene Expression Signatures in HR+/HER2- Early Breast Cancer  À¯Á¾ÇÑ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 09:35~10:00 Emerging Adjuvant Therapies in HR+/HER2- Early Breast Cancer : Are we ready for prime time?  ¼ÕÁÖÇõ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 10:00~10:25 Systemic treatment in HR+/HER2- Metastatic Breast Cancer : Current status & Future perspectives  ÀÓ½ÂÅÃ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 03-26 ¹éµÎȦ 10:25~10:35 Discussion  () 
È޽Ġ03-26  10:35~10:50 Break  () 
±³À°½Ã°£ 03-26 ¹éµÎȦ 10:50~11:15 Tailored approaches in Neoadjuvant/Adjuvant Systemic Therapy : Escalation vs. De-escalation  ¾È¼º±Í(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 11:15~11:40 Optimize Metastatic HER2+ Breast Cancer with Several anti-HER2 Treatment  ¹Ú°æÈ­(°í·ÁÀÇ´ë) 
Åä·Ð 03-26 ¹éµÎȦ 11:40~11:50 Discussion  () 
½Ä»ç 03-26  11:50~12:50 Lunch  () 
±³À°½Ã°£ 03-26 ¹éµÎȦ 12:50~13:15 Recent advances in Neoadjuvant/Adjuvant Chemotherapy : Immunotherapy, Chemotherapy  ¿øÇý¼º(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 13:15~13:40 Immune Checkpoint Inhibition for Metastatic TNBC : Is there an optimal combination?  À̼öÀÌ(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 13:40~14:05 Biomarker-driven therapeutic approaches in Metastatic TNBC  Ã¤ÀǼö(°æºÏÀÇ´ë) 
Åä·Ð 03-26 ¹éµÎȦ 14:05~14:15 Discussion  () 
È޽Ġ03-26  14:15~14:30 Break  () 
±³À°½Ã°£ 03-26 ¹éµÎȦ 14:30~14:55 Breast Cancer in Pregnancy  ¹è¼ö¿¬(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 14:55~15:20 Patients with Cardiac risk factors  Á¤¿ì¹é(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-26 ¹éµÎȦ 15:20~15:45 Systemic Treatment in Older Patients  ±èÁöÇü(¿¬¼¼ÀÇ´ë) 
Åä·Ð 03-26  15:45~15:55 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Çѱ¹À¯¹æ¾ÏÇÐȸ Á¦18ȸ Ç׾Ͽä¹ý ½ÉÆ÷Áö¾ö : 2022-03-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2022³â Á¦1Â÷ ´ëÇÑÇÙÀÇÇÐȸ Á¤µµ°ü¸® ½ÉÆ÷Áö¾ö : 2022-03-26
´ÙÀ½±Û ±¹¸³Áß¾ÓÀÇ·á¿ø °ñ´Ù°øÁõ Áø´Ü ¹× Ä¡·á¸¦ À§ÇÑ ¿öÅ©¼ó : 2022-03-26
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
92 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-24 0 306 2018-07-28
91 ¼­¿ï 2018³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãß°èÇмú´ëȸ(8/24) : 2018-08-24 0 323 2018-07-28
90 ÀÎõ °­È­±ºÀÇ»çȸ 3Â÷ ¼¼¹Ì³ª(°üÀýº¸Á¸ Ä¡·á) : 2018-08-24 0 316 2018-07-28
89 °æ±â Á¦5Â÷ ¾Æ½Ã¾ÆºÎÀÎÁ¾¾çÇÐȸ ¿öÅ©¼ó(ASGO 5th International Workshop on Gynecologic Oncology in conjunction with 12th KSGO Workshop for Young Gynecologic Oncologists) : 2018-08-24 0 483 2018-07-28
88 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] °Ç°­º¸Çè°ú ¹Î°£ÀǷẸÇè : 2018-08-23 0 296 2018-07-28
87 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-23 0 368 2018-07-28
86 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-22 0 475 2018-07-28
85 ¼­¿ï ´ëÇÑÀÓ»óÅëÁõÇÐȸ 2018³â Á¦2ȸ Á¤±âÇмúÁý´ãȸ : 2018-08-22 0 439 2018-07-28
84 °æºÏ ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ ´ë±¸°æºÏÁöȸ Á¦4Â÷ Áõ·ÊÅä·Ðȸ : 2018-08-21 0 421 2018-07-28
83 Ãæ³² ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ´ëÀüÃæûÁöȸ 8¿ù ¿¬¼ö°­Á : 2018-08-21 0 381 2018-07-28
82 °­¿ø ±¹¸³ÀÇ·á¿ø °ø°øÀÇ·á Consensus conference(3Â÷: °­¿ø±Ç) : 2018-08-20 0 437 2018-07-28
81 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ ¾à¹°Ä¡·á ¿¬¼ö°­Á : 2018-08-19 0 485 2018-07-28
80 ¼­¿ï Á¦16ȸ ±è¾È°úº´¿ø ½ÉÆ÷Áö¾ö : 2018-08-19 1 778 2018-07-28
79 ¼­¿ï 2018 ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ °³¿ø¼¼¹Ì³ª : 2018-08-19 0 697 2018-07-28
78 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦7ȸ ¿°Áõ¼º ÀåÁúȯ ¼¾ÅÍ ½ÉÆ÷Áö¾ö : 2018-08-19 0 335 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷